Biyopsi tanılı nonalkolik steatohepatit hastalarında fibrozis evrelerine göre metabolik sendrom komponentlerinin sıklıklarının karşılaştırılması: Metabolik bozukluk sayısındaki artış fibrozis progresyonunda etkili mi?

Year 2020, Volume: 20 Issue: 3, 143 - 149, 11.01.2022

Bahadır Köylü Yunus Günegül Cenk Sökmensüer Taylan Kav Erkan Parlak Bülent Sivri Onur Keskin

https://doi.org/10.17941/agd.1055288

Abstract

Giriş ve Amaç: Fibrozis evresi, nonalkolik steatohepatitte karaciğer ilişkili komplikasyonlar ve mortalite ile ilişkisi en kuvvetli olan histolojik parametredir. Nonalkolik steatohepatit hastalarında fibrozisin patogenezi halen tam olarak ortaya konulamamıştır ve eşlik eden tip 2 diyabet, obezite, hipertansiyon ve dislipideminin fibrozis progresyonundaki rolleri net değildir. Bununla beraber, eşlik eden metabolik bozuklukların sayısıyla fibrozis evresi arasında bir ilişki olması mümkündür. Gereç ve Yöntem: Bu çalışma tek merkezli, kesitsel bir çalışma olup bu çalışmada Ocak 2020-Ocak 2021 tarihleri arasında karaciğer biyopsisi yapılarak nonalkolik steatohepatit tanısı konulan 56 hastanın metabolik özellikleri, Ulusal Kolesterol Eğitim Programı/3. Erişkin Tedavi Paneli metabolik sendrom kriterleri temel alınarak değerlendirilmiştir. Nonalkolik Steatohepatit-Klinik Araştırma ağına göre yapılan fibrozis evrelemesi sonrasında, hastalar evre 2 ve üzeri fibrozisi ( ≥ F2) olanlar ve ≤ F1 fibrozisi olanlar şeklinde iki gruba ayrılmıştır. Bu iki grup arasında tip 2 diyabet, hipertansiyon, dislipidemi ve metabolik sendrom varlığı, vücut kitle indeksi, bel çevresi, kalça çevresi, bel çevresi/kalça çevresi oranı ve oluşturulan toplam metabolik sendromu puanı açısından karşılaştırma yapılmıştır. Bulgular: Fibrozis evrelemesi sonucunda ≤ F1 grubunda 23 hasta, ≥ F2 grubunda 33 hasta mevcuttur. Gruplar arasında tip 2 diyabet, hipertansiyon ve dislipidemi varlığı ile vücut kitle indeksi, bel çevresi, kalça çevresi, bel çevresi/kalça çevresi oranı açısından anlamlı bir fark saptanmazken, metabolik sendrom varlığı açısından anlamlı bir fark mevcuttur ( ≥ F2 grubunda %84.8 ve ≤ F1 grubunda %47.8; p = 0.001). Toplam metabolik sendrom puanı ≥ F2 grubunda anlamlı olarak daha yüksek olup bu gruptaki hastaların %60.6’sında 4 puan ve üzerindedir (p < 0.001). Korelasyon analizinde fibrozis evresi ile toplam metabolik sendrom puanı arasında istatistiksel açıdan anlamlı, orta derecede korelasyon saptanmıştır (r = 0.48, p < 0.001). Sonuç: Toplam metabolik sendrom puanı kolay hesaplanabilir bir yöntem olup nonalkolik steatohepatit hastalarında fibrozis progresyonu riskinin değerlendirilmesinde kullanılabilir.

Keywords

Steatohepatit, karaciğer fibrozisi, metabolik sendrom

Comparison of the frequencies of metabolic syndrome components according to fibrosis stages in biopsy-proven nonalcoholic steatohepatitis patients: Does increased number of metabolic dysregulation have an effect on fibrosis progression?

Abstract

Background and Aims: Fibrosis stage is the histologic parameter that has the strongest association with liver-related complications and mortality in nonalcoholic steatohepatitis. The pathogenesis of fibrosis in nonalcoholic steatohepatitis patients has still not been fully elucidated, and the roles of concomitant type 2 diabetes, obesity, hypertension and dyslipidemia in the progression of fibrosis are unclear. However, there may be an association between the number of accompanying metabolic dysregulations and fibrosis stage in a number-dependent manner. Materials and Methods: In this single-center, cross-sectional study, 56 patients with the diagnosis of biopsy-proven nonalcoholic steatohepatitis were enrolled between January 2020 and January 2021, and the metabolic characteristics of these patients were evaluated on the basis of National Cholesterol Education Program/Adult Treatment Panel III metabolic syndrome criteria. After fibrosis staging according to Nonalcoholic Steatohepatitis Clinical Research Network, patients were divided into two groups as those with fibrosis stage ≥ F2, and those with fibrosis stage ≤ F1. Comparison between these two groups in terms of the presence of type 2 diabetes, hypertension, dyslipidemia and metabolic syndrome, total metabolic syndrome score, body mass index, waist circumference, hip circumference and waist circumference/hip circumference ratio has been made. Results: After grouping of patients according to fibrosis stages, there were 23 patients in ≤ F1 group and 33 patients in ≥ F2 group. While there was no significant difference between the groups in terms of presence of type 2 diabetes, hypertension and dyslipidemia, body mass index, waist circumference, hip circumference and waist circumference/hip circumference ratio, there was a significant difference for the presence of metabolic syndrome (84.8% in ≥ F2 group and 47.8% in ≤ F1 group; p = 0.001). The total metabolic syndrome score was significantly higher in ≥ F2 group and it was 4 points or more in 60.6% of the patients in this group. In the correlation analysis, a statistically significant and moderate correlation was found between the fibrosis stage and total metabolic syndrome score (r = 0.48, p < 0.001). Conclusion: Total metabolic syndrome score is an easily calculated method and can be used to evaluate the risk of fibrosis progression in nonalcoholic steatohepatitis patients.

Keywords

Steatohepatitis, liver fibrosis, metabolic syndrome

References

• 1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11-20.
• 2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57.
• 3. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-54.e1-9; quiz e39-40.
• 4. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 2017;377:2063-72.
• 5. Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci 2016;17:774.
• 6. Hagstrom H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017;67:1265-73.
• 7. Yang RX, Zou ZS, Zhong BH, et al. The pathologic relevance of metabolic criteria in patients with biopsy-proven non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China. Pancreat Dis Int 2021;20:426-32. Epub 2021 Jun 25.
• 8. Kleiner DE, Brunt EM, Van Natta M, et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
• 9. Expert Panel on Detection E, Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
• 10. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-44.
• 11. Yilmaz Y, Kani HT, Demirtas CO, et al. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. Turk J Gastroenterol 2019;30:892-8.
• 12. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409-15.
• 13. DeBoer MD, Lin B, Filipp SL, Cusi K, Gurka MJ. Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis. Nutr Res 2021;88:34-43.
• 14. Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol 2019;70:531-44.
• 15. Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 2019;71:793-801.
• 16. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010;59:1410-5.